Regranex Logo
For US Healthcare Professionals only.

IMPORTANT SAFETY INFORMATION

An increased rate of mortality secondary to malignancy was
observed in patients treated with 3 or more tubes of REGRANEX® Gel
in a postmarketing retrospective cohort study. View More.


TERMS OF USE

These terms and conditions apply when you use our website. By using this website, you are deemed to agree to these terms and conditions. If you do not agree to abide by all of these terms, please do not visit our website.

Smith & Nephew provides this website for your general information only, and we reserve the right to delete, modify or supplement the content of this website (including these terms) at any time for any reason without notification to anyone.

We do our best to ensure that the information on this website is accurate and helpful at all times. However, we cannot ultimately warrant the accuracy of that information and so we cannot be held liable for any use or reliance you may make of or put on it.

The information on this website is time-based, and may well no longer be an accurate reflection of our current position.

Nothing on this website should be construed as an offer to provide any service to you. No offer to contract shall be provided by us from this website, and any offer must be signed by an officer of the company.

Contributions

Other than those circumstances described in the Privacy Policy on this website, any contributions you send to this website are on a non-confidential basis, and we are under no obligation to refrain from reproducing, publishing, or otherwise using them in any way or for any purpose. That means that Smith & Nephew shall be free to use the content of any such communications, including any ideas, inventions, concepts, techniques or know-how disclosed therein, for any purpose without compensation or attribution to you, including developing, manufacturing and/or marketing goods or services.

So please do NOT submit any confidential information to us; anything you submit will not be held in confidence, but will be treated as publicly-available information.

Warranty and Liability

Smith & Nephew makes no representations, warranties or assurances as to the availability, accuracy, currency or completeness of this website or its contents. We shall not be liable for any damages or injury resulting from your access to, or inability to access this website, or from your reliance on any information provided at this website.

Unless otherwise noted, product labelling is for the country shown. Products shown may not be available in all countries or may be known by a different name. Indications for use may vary from country to country. You should always check with your local health care professional and/or read the package insert prior to use. Customer Service is available to help with product information or questions. The information provided here is not a substitute for medical care. If you have or suspect you have a health problem, you should consult your health care professional.

We will not be liable for any loss, damage, expense, costs, delays or other liability whatsoever (including without limitation any financial losses such as loss of profit) which you may incur as a result of any event (including without limitation any failure of transmission, communication, computer or other facilities or your inability to access the website for any reason or any failure, error or delay in the sending or receiving of any notice or communication or instruction through the post or any electronic medium).

You acknowledge that information and software accessible over the internet may contain viruses, and other malicious and damaging objects. You acknowledge that it is your responsibility to adequately protect yourself as you browse websites, and that we shall not be liable for any loss which results from your access to this website.

With the exception of websites under our control, if this website is linked to/from other websites, or if other websites are linked to/from this website, Smith & Nephew does not endorse or have any responsibility for the content of such other websites, and Smith & Nephew shall not be liable for any damages or injury arising from the content of any other website.

Intellectual Property

The content of this website is owned or controlled by Smith & Nephew and is protected under applicable copyright and trademark laws. You may download content only for your personal use for non-commercial purposes, but no modifications or further reproduction of the content is permitted without the express prior written permission of Smith & Nephew. The content otherwise may not be copied or used in any way.

The ownership of the copyright on all content, including content contributed by users of the website is held by Smith & Nephew, and its use is expressly forbidden without our prior consent in writing. You acknowledge the transfer of ownership of copyright to Smith & Nephew of anything that you contribute to the website.

All trademarks are acknowledged

The trademarks displayed are registered and nothing contained in these conditions or the website should be construed as granting any licence or right to use any of the trademarks without our permission. However, copying and printing of those web pages which contain the trademarks is permitted within the scope of the licence set forth below.

You may download to a local hard disk and print extracts from the website solely for personal, non-commercial use. You may also recopy downloaded extracts to others for their personal, non-commercial use.

You may not reproduce part or all of the contents of the website in any form unless it is for personal, non-commercial use.

You may not copy or otherwise incorporate into or store in any other website, electronic retrieval system, publication or other work any of the content of the website in any form (whether hard copy, electronic or other).

You may link to our home page, or other pages on our website, provided you do so in a way that is fair and legal and does not damage our reputation or take advantage of it. However you must not establish a link in such a way as to suggest any form of association, approval or endorsement on our part where none exists.

You must not establish a link from any website that is not either owned or controlled by you.

Our website must not be framed on any other website.

If you wish to make any use of material on our website other than that set out above, please address your request to enquiries@smith-nephew.com

General

Smith & Nephew PLC, registered office 15 Adam St, London, United Kingdom, WC2N 6LA, is a holding company and is not an operating company. Therefore, products and services are provided exclusively by subsidiaries and not by Smith & Nephew PLC. "Smith & Nephew" may refer to Smith & Nephew PLC itself or one or more of its subsidiaries.

With the exception of websites under our control, if this website is linked to/from other websites, or if other websites are linked to/from this website, Smith & Nephew does not endorse or have any responsibility for the content of such other websites, and Smith & Nephew shall not be liable for any damages or injury arising from the content (or the use of your data) of any other website.

This statement is subject to change, and Smith & Nephew will not proactively notify you of any such changes. It is your responsibility to ensure you visit this web page regularly to review any changes that may have been made since your previous visit.

This agreement shall be governed by the laws of the state of Tennessee and any disputes subject to the exclusive jurisdiction of the United States of America.

This statement was last updated on 5 November 2012.

Copyright © 2015 Smith & Nephew

IMPORTANT SAFETY INFORMATION

WARNING: INCREASED RATE OF MORTALITY SECONDARY TO MALIGNANCY

An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of REGRANEX® Gel in a postmarketing retrospective cohort study. REGRANEX® Gel should only be used when the benefits can be expected to outweigh the risks. REGRANEX® Gel should be used with caution in patients with known malignancy.

Indication and limitations of use

REGRANEX® (becaplermin) Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply. REGRANEX® Gel is indicated as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control.

  • The efficacy of REGRANEX® Gel has not been established for the treatment of pressure ulcers and venous stasis ulcers and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (Stage I or II, IAET staging classification) or ischemic diabetic ulcers.
  • The effects of REGRANEX® Gel on exposed joints, tendons, ligaments, and bone have not been established in humans.
  • REGRANEX® Gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention.

Contraindications

REGRANEX® Gel is contraindicated in patients with known neoplasm(s) at the site(s) of application. REGRANEX® Gel is contraindicated in patients with known hypersensitivity to any component of the product (e.g., parabens).

Warnings and precautions

Malignancies distant from the site of application have been reported in both a clinical study and in postmarketing use. REGRANEX® Gel should be used with caution in patients with a known malignancy.

If application site reactions occur, the possibility of sensitization or irritation caused by parabens or m-cresol should be considered.

Commonly observed adverse reactions

In clinical trials, erythematous rashes occurred in 2% of patients treated with REGRANEX® Gel (and good ulcer care) or placebo (and good ulcer care), and none in patients receiving good ulcer care alone.

See warnings above regarding malignancy.

Burning sensation at the site of application and erythema have been reported during post-approval use of REGRANEX® Gel.

Other important information

The amount of REGRANEX® Gel to be applied should be recalculated by the physician or wound caregiver at weekly or biweekly intervals depending upon the rate of change in ulcer area.

If the ulcer does not decrease in size by approximately 30% after 10 weeks of treatment or complete healing has not occurred in 20 weeks, continued treatment with REGRANEX® Gel should be reassessed.

Pregnancy & Nursing Mothers: Pregnancy Category C. REGRANEX® Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether becaplermin is excreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when REGRANEX® Gel is administered to nursing women.

Safety and effectiveness of REGRANEX® Gel in pediatric patients below the age of 16 years have not been established.

Counsel patients to review the Medication Guide and to discuss any questions or concerns with their healthcare provider before starting REGRANEX® Gel and at regular intervals during treatment, including when their prescription is refilled.

To report suspected adverse reactions, contact Smith & Nephew at 1-800-441-8227 or contact FDA at www.fda.gov/medwatch or at 1-800-FDA-1088.

Please see accompanying full Prescribing Information and Medication Guide.

This information is intended for healthcare professionals in the United States and is not intended for the general public.